Alcohol-Associated Hepatitis Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
See the next evidence inflection points before they arrive. This readout-outlook report connects Clinical Trials, Drug & Asset, and Company & Deal Intelligence data through PatSnap MCP Servers. Explore the PatSnap MCP Marketplace to monitor the same endpoint, sponsor and timing signals inside your own AI workflow.
MCP evidence snapshot: 16 July 2026; publication date: 17 July 2026. This is strategic research, not medical advice. Trial status, endpoints and timing can change; confirm the underlying records before making decisions.
Readout outlook: why this landscape matters now
Alcohol-Associated Hepatitis remains an active clinical development field. Development is moving beyond single surrogate measures toward integrated cardiometabolic, renal and clinical-outcome evidence, with convenience and persistence becoming major differentiators. The PatSnap evidence set used here contains 45 matched trial records and 51 indexed result records before the decision-focused sample below was selected. This companion outlook shifts the decision lens from market breadth to evidence timing: which endpoints can change practice, which sponsors can execute across geographies, and where the next readout may still leave uncertainty.
MCP workflow for a readout-focused landscape
The analysis starts with Clinical Trials MCP and clinical_trial_fetch to align phase, recruitment status, sponsor, countries, primary endpoints and completion dates. clinical_trial_result_fetch then separates already indexed evidence from future catalysts. Drug & Asset drug_fetch adds mechanism and global development status; Company & Deal Intelligence organization_fetch adds sponsor context. Use PatSnap MCP Servers to keep each layer traceable instead of inferring asset or company facts from trial titles.
Trial, endpoint and expected-readout map
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| JPRN-UMIN000061896 | Intervention not normalized | Not Applicable; 一般募集中/Open public recruiting | Kagawa University | Japan | ADH1B低活性×ALDH2活性の遺伝子型とSAH発症の関連 ; Association between ADH1B low-activity / ALDH2 active genotype and the onset of severe alcoholic hepatitis (SAH) | 2028-09-30 |
| NCT07465588 | Intervention not normalized | Not Applicable; Not yet recruiting | The Massachusetts General Hospital | Geography not listed | Alcohol Abstinence Measured by PEth (12 weeks) | 2028-03-31 |
| NCT07428538 | Larsucosterol | Phase 3; Recruiting | Bausch Health Americas, Inc. | United States | Transplant Free Survival up to Day 90 (Up to Day 90) | 2027-11-01 |
| NCT07262515 | Intervention not normalized | Not Applicable; Recruiting | Assistance Publique des Hôpitaux de Paris SA | France | Overall survival after diagnosis of acute alcoholic hepatitis (From diagnosis up to 7 years after) | 2025-12-01 |
Read the table horizontally. Phase shows nominal maturity, but endpoint choice shows what the study can actually prove; geography signals operational breadth; and expected timing reveals whether a program is a near-term catalyst or a long-duration strategic bet.
Readout signals already on record
- Aldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules (Phase 2): the indexed record reports MELD score = Relative to baseline, statistically significant improvement was observed in clinically relevant objective markers of hepatic function and inflammation, including the Model for End-Stage Liver Disease (MELD) score (P=0.001).
- IL-1 Signal Inhibition in Alcoholic Hepatitis (ISAIAH) (Phase 2): the indexed record reports Number of Patients Presenting Histological Improvement of Alcoholic Hepatitis on Liver Biopsy After 28 Days of Treatment Compared to Baseline. = 10 Participants; Number of Patients Presenting Histological Improvement of Alcoholic Hepatitis on Liver Biopsy After 28 Days of Treatment Compared to Baseline.: Mean Difference (Net) = 16.7(95% CI, -11.2 to 44.5), P-Value = 0.248; Number of Patients Presenting Histological Improvement of Alcoholic Hepatitis on Liver Biopsy After 28 Days of Treatment Compared to Baseline.: Mean Difference (Net) = 16.7(95% CI, -11.2 to 44.5), P-Value = 0.248.
- Effect of terlipressin on patients with hepatorenal syndrome, alcohol-associated hepatitis, and acute-on-chronic liver failure grade 0–2 (Phase 3): the indexed record reports HRS reversal = 11.7 %; HRS reversal = 44.0 %.
These signals are anchors, not league tables. Differences in population, prior treatment, baseline risk, estimand, endpoint definition and follow-up can overwhelm apparent numerical comparisons. The useful question is which uncertainty each result resolves before the next catalyst.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
How assets and sponsors shape readout probability
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including Larsucosterol (Phase 3; DNMTs). Company & Deal Intelligence records identify sponsor context for Kagawa University, The Massachusetts General Hospital, Bausch Health Americas, Inc. (VRX), Assistance Publique des Hôpitaux de Paris SA. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Evidence white space before the next readout cycle
- Active-comparator trials on top of contemporary standard of care.
- Hard cardiovascular, kidney or liver outcomes linked to earlier biomarker change.
- Evidence in underrepresented populations and patients with multiple comorbidities.
- Durability, adherence and post-discontinuation outcomes.
Readout-risk implications
A crowded field does not guarantee a crowded evidence set. Programs can still differentiate through an active comparator, a clinically meaningful endpoint, a biomarker-defined responder group, broader geography, or a credible sequencing plan. Sponsors should pressure-test whether the planned readout will close a decision gap; BD teams should distinguish mechanism novelty from evidence novelty; investors should track endpoint maturity and execution risk alongside phase.
Readout watchlist
Monitor recruitment changes, protocol amendments, primary-completion dates, new result indexing, sponsor ownership and multinational expansion. Re-run the MCP workflow as a delta analysis. A change from surrogate to clinical outcome, a delayed completion date, a new active comparator or a scaled partner can materially alter the probability and strategic meaning of the next readout.
Bottom line
Alcohol-Associated Hepatitis has multiple clinical catalysts, but their value depends on endpoint quality, execution and context. A readout outlook is most useful when it joins trial design, indexed results, asset mechanism and sponsor capacity in one traceable view.
Build your own readout monitor: Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable components for catalyst tracking and SEO-ready reports.
